| Model evaluation of continuous data pharmacometric models: metrics and graphics THT Nguyen, MS Mouksassi, N Holford, N Al‐Huniti, I Freedman, ... CPT: pharmacometrics & systems pharmacology 6 (2), 87-109, 2017 | 299 | 2017 |
| Asthma and insulin resistance in morbidly obese children and adolescents BA Al-Shawwa, NH Al-Huniti, L DeMattia, W Gershan Journal of Asthma 44 (6), 469-473, 2007 | 122 | 2007 |
| Multiple‐dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects R Krishna, AJ Bergman, B Jin, M Fallon, J Cote, P Van Hoydonck, ... Clinical Pharmacology & Therapeutics 84 (6), 679-683, 2008 | 107 | 2008 |
| Hypercholesterolemia is a potential risk factor for asthma B Al-Shawwa, N Al-Huniti, G Titus, M Abu-Hasan Journal of Asthma 43 (3), 231-233, 2006 | 105 | 2006 |
| The identification of potent, selective, and orally available inhibitors of ataxia telangiectasia mutated (ATM) kinase: the discovery of AZD0156 (8-{6-[3-(Dimethylamino … KG Pike, B Barlaam, E Cadogan, A Campbell, Y Chen, N Colclough, ... Journal of medicinal chemistry 61 (9), 3823-3841, 2018 | 104 | 2018 |
| Radiation and PD-(L) 1 treatment combinations: immune response and dose optimization via a predictive systems model Y Kosinsky, SJ Dovedi, K Peskov, V Voronova, L Chu, H Tomkinson, ... Journal for immunotherapy of cancer 6, 1-15, 2018 | 91 | 2018 |
| Joint longitudinal and time-to-event models for multilevel hierarchical data SL Brilleman, MJ Crowther, M Moreno-Betancur, J Buros Novik, J Dunyak, ... Statistical Methods in Medical Research 28 (12), 3502-3515, 2019 | 73 | 2019 |
| Predictive performance of physiologically based pharmacokinetic and population pharmacokinetic modeling of renally cleared drugs in children W Zhou, TN Johnson, H Xu, SYA Cheung, KH Bui, J Li, N Al‐Huniti, ... CPT: pharmacometrics & systems pharmacology 5 (9), 475-483, 2016 | 65 | 2016 |
| Predictive performance of physiologically based pharmacokinetic (PBPK) modeling of drugs extensively metabolized by major cytochrome P450s in children W Zhou, TN Johnson, KH Bui, SYA Cheung, J Li, H Xu, N Al‐Huniti, ... Clinical Pharmacology & Therapeutics 104 (1), 188-200, 2018 | 59 | 2018 |
| Single‐dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects R Krishna, A Garg, D Panebianco, J Cote, AJ Bergman, P Van Hoydonck, ... British journal of clinical pharmacology 68 (4), 535-545, 2009 | 58 | 2009 |
| An integrated pharmacodynamic analysis of erythropoietin, reticulocyte, and hemoglobin responses in acute anemia P Veng-Pederson, S Chapel, PRL Schmidt, NH Al-Huniti, RT Cook, ... Pharmaceutical research 19, 1630-1635, 2002 | 49 | 2002 |
| Reporting guidelines for population pharmacokinetic analyses K Dykstra, N Mehrotra, CW Tornøe, H Kastrissios, B Patel, N Al-Huniti, ... Journal of pharmacokinetics and pharmacodynamics 42, 301-314, 2015 | 48 | 2015 |
| Simulation and prediction of the drug‐drug interaction potential of naloxegol by physiologically based pharmacokinetic modeling D Zhou, K Bui, M Sostek, N Al‐Huniti CPT: pharmacometrics & systems pharmacology 5 (5), 250-257, 2016 | 41 | 2016 |
| Pharmacokinetic tracer kinetics analysis of changes in erythropoietin receptor population in phlebotomy‐induced anemia and bone marrow ablation P Veng‐Pedersen, S Chapel, NH Al‐Huniti, RL Schmidt, EM Sedars, ... Biopharmaceutics & drug disposition 25 (4), 149-156, 2004 | 37 | 2004 |
| Evaluation of the drug–drug interaction potential of acalabrutinib and its active metabolite, ACP‐5862, using a physiologically‐based pharmacokinetic modeling approach D Zhou, T Podoll, Y Xu, G Moorthy, K Vishwanathan, J Ware, JG Slatter, ... CPT: pharmacometrics & systems pharmacology 8 (7), 489-499, 2019 | 36 | 2019 |
| Model evaluation group of the international society of pharmacometrics (ISoP) best practice committee TH Nguyen, MS Mouksassi, N Holford, N Al-Huniti, I Freedman, ... Model evaluation of continuous data pharmacometric models: metrics and …, 2017 | 33 | 2017 |
| Pharmacodynamic analysis of changes in reticulocyte subtype distribution in phlebotomy-induced stress erythropoiesis NH Al-Huniti, JA Widness, RL Schmidt, P Veng-Pedersen Journal of pharmacokinetics and pharmacodynamics 32, 359-376, 2005 | 33 | 2005 |
| Change in erythropoietin pharmacokinetics following hematopoietic transplantation JA Widness, RL Schmidt, RJ Hohl, FD Goldman, NH Al‐Huniti, KJ Freise, ... Clinical Pharmacology & Therapeutics 81 (6), 873-879, 2007 | 32 | 2007 |
| The effect of quinidine, a strong P‐glycoprotein inhibitor, on the pharmacokinetics and central nervous system distribution of naloxegol K Bui, F She, D Zhou, K Butler, N Al‐Huniti, M Sostek The Journal of Clinical Pharmacology 56 (4), 497-505, 2016 | 31 | 2016 |
| Assessing pharmacokinetic differences in Caucasian and East Asian (Japanese, Chinese and Korean) populations driven by CYP2C19 polymorphism using physiologically-based … L Zhou, P Sharma, KR Yeo, M Higashimori, H Xu, N Al-Huniti, D Zhou European Journal of Pharmaceutical Sciences 139, 105061, 2019 | 29 | 2019 |
Mark Sostek, M.D., A.G.A.F., F.A.C.G.Seres TherapeuticsVerified email at serestherapeutics.com
